Loading clinical trials...
Loading clinical trials...
Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Lingzhi(Ganoderma) is widely used in traditional Chinese medicine. Previous studies indicated that Lingzhi was safe, well tolorated, and improved symptoms as an add-on therapy to levodopa in early Parkinson's disease(PD) patients. Here the investigators design a multicenter, randomized, double-blind, placebo-controlled, delayed-start trial to evaluate the effects of Lingzhi on modifying disease progression in untreated PD patients.
Age
30 - 80 years
Sex
ALL
Healthy Volunteers
No
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Start Date
July 15, 2018
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2021
Last Updated
August 26, 2021
288
ESTIMATED participants
Ganoderma
DRUG
Placebos
DRUG
Lead Sponsor
Xuanwu Hospital, Beijing
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640